Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2019

View Archived Issues

World AIDS Day: Immediate ART initiation for neonates with HIV-1 provides significant benefits

New selective and potent mTOR inhibitor discovered through structure-based drug design

Evaluation of neuronal responses to La Crosse virus infection in human cerebral organoids

Chidamide approved in China for breast cancer indication

Takeda presents 18-month data from pivotal phase III TIDES study of TAK-003 dengue vaccine

Apatinib demonstrates safety and efficacy in phase II study in adenocarcinoma of the head and neck

Roche publishes data from iMATRIX study of atezolizumab

MiR-125b as a novel target in diabetes

Avidin describes new apoptosis inducers

Shenzhen Salubris Pharmaceuticals identifies new PAR-4 antagonists

Beijing Innocare Pharmaceutical Technology patents VEGFR inhibitors

New prostanoid EP3 receptor antagonists synthesized at Bayer

IBD Therapeutics discloses TRPM8 and TrpV1 antagonists/opioid receptor agonists

Mouse model reveals role of Rap1A in heart function

Developmental origins of pediatric brain tumors

Study links long non-coding RNAs to pulmonary hypertension

Vi-DT typhoid conjugate vaccine begins phase III study in Nepal

Pharmacodynamic responses seen with RNA interference therapy ARO-ANG3 in healthy volunteers

Aslan reports preliminary proof-of-concept data on ASLAN-004 in atopic dermatitis

Proof-of-concept study of SENS-111 in acute unilateral vestibulopathy misses primary endpoint

Concert initiates phase II study of CTP-692 as adjunctive treatment in schizophrenia

Phase IIb trial of Amphora for prevention of chlamydia and gonorrhea meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...